Prenetics Global Limited

NasdaqGM PRE

Prenetics Global Limited EBIT Margin for the year ending December 31, 2023: -256.13%

Prenetics Global Limited EBIT Margin is -256.13% for the year ending December 31, 2023, a -218.41% change year over year. EBIT ratio is the ratio of EBIT to revenue, measuring a company's operating profitability without considering non-operating income or expenses.

Prenetics Global Limited EBIT Margin for the year ending December 31, 2022 was -80.44%, a -34.45% change year over year.
Prenetics Global Limited EBIT Margin for the year ending December 31, 2021 was -59.83%, a -915.07% change year over year.
Prenetics Global Limited EBIT Margin for the year ending December 31, 2020 was -5.89%, a 97.38% change year over year.
Prenetics Global Limited EBIT Margin for the year ending December 31, 2019 was -225.31%.

Key data

Date	EBIT Margin	EPS (Basic)	EPS (Diluted)	Shares (Basic, Weighted)

NasdaqGM: PRE

Prenetics Global Limited

CEO	Mr. Sheng Wu Yeung
IPO Date	July 16, 2021
Location	Hong Kong
Headquarters	Unit 701-706, K11 Atelier King’s Road
Employees	320
Sector	Healthcare
Industries Biotechnology Cleaning Supplies Clinical Trials Drugstores & Retail Pharmacies Eyewear Medical Instruments Personal Care Pharmaceuticals

Description

Prenetics Global Limited, an investment holding company, operates as a diagnostics and genetic testing company. Its products include CircleDNA, a consumer genetic testing product; and Circle HealthPod, a rapid detection health monitoring system that allows users to take COVID-19 tests at point-of-care or at home utilizing the nucleic acid amplification test. The company's products also comprise ColoClear, a non-invasive FIT-DNA colorectal cancer screening test; Circle SnapShot, an off-the-shelf at-home blood test; Circle Medical, a diagnostic testing product; and Circle One and F1x/Fem. Prenetics Global Limited was founded in 2014 and is headquartered in Quarry Bay, Hong Kong.

Key trends

Past 5 years